Standardized Measurement of Femoral Artery Depth by Computed Tomography to Predict Vascular Complications After Transcatheter Aortic Valve Implantation
Section snippets
METHODS
Between January 2013 and December 2018, 1,411 consecutive patients were prospectively included in our TAVI database. All patients selected by our multidisciplinary team had severe symptomatic aortic stenosis and gave written informed consent. Patients who had TAVI via a nonfemoral route and who did not have CT in our center or when CT was not archived were excluded. The study was approved by our local ethics committee with a waiver for retrospective analysis.
Pre-procedural MDCT examinations
RESULTS
The flowchart of the studied population is presented in Figure 2. From January 2013 to December 2018, 1,411 patients had TAVI in our center. Among them, 182 (12.9%) patients were excluded because they were implanted via a nonfemoral route. An additional 540 (38.3%) TF TAVI patients were excluded because MDCT was performed in another center or was not archived in the picture archiving computerized system (PACS) currently used in our center (Carestream, Rochester, New York). Thus, 689 (55.7%) TF
DISCUSSION
We aimed to evaluate a new MDCT parameter (i.e., measurement of FAD), in addition to usual parameters, to predict major VCs and the need for a stent-graft after TF TAVI. The main results can be summarized as follows: (1) FAD measurement using standardized MDCT is easy and reproducible and was significantly increased in patients requiring a stent-graft; (2) FAD was the only predictor of the need for a stent-graft although ROC curve analysis indicated poor accuracy with a threshold value of
CREDIT AUTHOR STATEMENT
Eric Durand, Jean Nicolas Dacher and Helene Eltchaninoff have contributed to conception and design, acquisition of data, analysis and interpretation of data, drafting and revisiting the manuscript; Eric Durand has performed statistical analysis; Marylin penso, Stephanie Wong Thibault Hemery, Thomas Levesque, Gustavo Moles, Christophe Tron, Najime Bouhzam, Nicolas Bettinger have contributed to acquisition and interpretation of data.
DECLARATION OF COMPETING INTEREST
Eric Durand has received lecture fees from Edwards Lifesciences.
ACKNOWLEDGMENT
The authors are grateful to Nikki Sabourin-Gibbs for her help in editing the manuscript. Professors Eric Durand and Hélne Eltchaninoff have received a grant by the French Government, managed by the National Research Agency (ANR) under the program “Investissements d'avenir” with the reference ANR-16-RHU-0003.
REFERENCES (24)
- et al.
PARTNER Trial Investigators. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial
J Am Coll Cardiol
(2012) - et al.
Computed Tomography Imaging in the Context of Transcatheter Aortic Valve Implantation (TAVI)/Transcatheter Aortic Valve Replacement (TAVR): an expert consensus document of the Society of Cardiovascular Computed Tomography
JACC Cardiovasc Imaging
(2019) - et al.
Transfemoral aortic valve implantation new criteria to predict vascular complications
JACC Cardiovasc Interv
(2011) - et al.
Incidence, predictors, and impact of vascular complications after transfemoral transcatheter aortic valve implantation with the SAPIEN 3 prosthesis
Am J Cardiol
(2018) - et al.
Comparison of the risk of vascular complications associated with femoral and radial access coronary catheterization procedures in obese versus nonobese patients
Am J Cardiol
(2004) - et al.
Transfemoral aortic valve replacement with the Edwards SAPIEN and Edwards SAPIEN XT prosthesis using exclusively local anesthesia and fluoroscopic guidance: feasibility and 30-day outcomes
JACC Cardiovasc Interv
(2012) - et al.
Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation
Am J Cardiol
(2014) - et al.
Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement
JACC Cardiovasc Interv
(2016) - et al.
Meta-analysis of effect of body mass index on outcomes after transcatheter aortic valve implantation
Am J Cardiol
(2017) - et al.
Vascular closure device failure in contemporary practice
JACC Cardiovasc Interv
(2012)
Factors in ProGlide vascular closure failure in sheath arteriotomies greater than 16 French
Eur J Vasc Endovasc Surg
Computed tomographic angiography-derived risk factors for vascular complications in percutaneous transfemoral transcatheter aortic valve implantation
Am J Cardiol
Cited by (9)
Sunshine after the nightmare: Iliac artery injury during coarctaion of aorta stenting in an adolescent girl
2023, Progress in Pediatric CardiologyPredicting complications for patient suitability
2023, Revista Portuguesa de CardiologiaUltrasound-Guided Versus Conventional MANTA Vascular Closure Device Deployment After Transcatheter Aortic Valve Implantation
2022, American Journal of CardiologyCitation Excerpt :The following measurements were obtained in all patients on the side of delivery sheath placement at the level of the CFA: minimum, mean, and maximum lumen diameter of the vessel at the minimum lumen diameter (MLD) level of the targeted CFA and degree of calcification based on MANTA femoral artery calcification score (MFACS).14 CFA depth was determined as the distance between the skin and the center point of the CFA, as described previously.18 The primary endpoint of this study was MANTA-related VC at 30 days after TAVI.
Successfully Managed Access-Site Complication Was Not Associated With Worse Outcome After Percutaneous Transfemoral Transcatheter Aortic Valve Implantation: Up-to-Date Insights From the OCEAN-TAVI Registry
2022, Cardiovascular Revascularization MedicineCitation Excerpt :The mechanism by which lower BMI patients had an excess of these complications is unclear, but it could be related to the presence of severe, non-cardiovascular, underlying diseases in very lean patients, as shown in previous trials [12]. SFAR has been proposed as an independent predictor of vascular complications in various studies, even if the expandable eSheath system and InLine sheath enable less-invasive percutaneous TF-TAVI [4,13–14]. In this study, the incidence of access-site complications declined year-by-year, irrespective of the increasing number of percutaneous TF-TAVI.
Computed tomography derived anatomical predictors of vascular access complications following transfemoral transcatheter aortic valve implantation: A systematic review
2024, Catheterization and Cardiovascular Interventions